We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Safety of jakinibs: lessons from ORAL Surveillance.
- Authors
Bukhari, Marwan; Bergman, Martin; Giles, Jon T; Lozada, Carlos; Cush, John; Yamaoka, Kunihiro; McKay, Catriona; Kavanaugh, Arthur
- Abstract
The article discusses the ORAL Surveillance study on the jakinibs methotrexate (MTX) agent's safety for major adverse cardiac events (MACE) and malignancies, excluding non-melanoma skin cancer (NMSC). Topics covered include the safety question with different ex vivo specificity for other Janus kinase enzymes, the U.S. Food and Drug Administration's (FDA) required labelling for jakinibs, and the study's alert on the serious outcome potential in rheumatoid arthritis (RA) patients.
- Subjects
ANTI-inflammatory agents; MAJOR adverse cardiovascular events; JANUS kinases; TREATMENT effectiveness; METHOTREXATE; RHEUMATOID arthritis; DRUG labeling; NEUROTRANSMITTER uptake inhibitors; PATIENT safety
- Publication
Rheumatology, 2022, Vol 61, Issue 11, p4223
- ISSN
1462-0324
- Publication type
Editorial
- DOI
10.1093/rheumatology/keac166